Quantcast

Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes Boehringer Ingelheim’s Disclosures Regarding Growing Pradaxa Bleeding Litigation

February 15, 2014

The Firm is evaluating Pradaxa lawsuits on behalf of individuals who suffered cerebral hemorrhage, gastrointestinal bleeding, and other serious bleeding events, allegedly due to Pradaxa.

New York, New York (PRWEB) February 15, 2014

Boehringer Ingelheim has acknowledged being named a defendant in more than 2,000 Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) pending in U.S. courts that allege the company failed to warn patients about the potential for serious and uncontrollable bleeding associated with Pradaxa. According to a report published by Reuters, despite the growing litigation, the company maintains that the risk of Pradaxa bleeding side effects was known, and need to be weighed against the drug's life saving potential.*

“Our Firm hears from alleged victims of Pradaxa bleeding on a regular basis. It’s not surprising at all that the number of claims involving the blood thinner has surpassed 2,000,” says Bernstein Liebhard LLP, nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to individuals who suffered cerebral hemorrhage, gastrointestinal bleeding, and other serious episodes of internal bleeding, allegedly due to Pradaxa.

Pradaxa Bleeding Litigation

According to court documents, the majority of Pradaxa lawsuits involving the drug’s bleeding side effects are pending in a multidistrict litigation underway in U.S. District Court, Southern District of Illinois. All of the claims accuse Boehringer Ingelheim of failing to inform doctors and patients that there exists no readily available agent to reverse the serious internal bleeding that sometimes occurs with Pradaxa. The claims point out that Pradaxa was touted as an improvement over warfarin, even though bleeding that can occur in relation to that decades-old blood thinner can be stopped quickly via the administration of vitamin K. The litigation’s first trials are scheduled to get underway in August. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

According to Reuters, Pradaxa was the first among a new class of blood thinners intended to replace warfarin to prevent strokes in people with atrial fibrillation. In December 2013, the U.S. Food & Drug Administration (FDA) announced a new, large-scale assessment of Pradaxa bleeding rates in relation to warfarin

Alleged victims of serious and uncontrollable Pradaxa bleeding may be entitled to compensation from Boehringer Ingelheim. To learn more about filing a Pradaxa lawsuit please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to schedule a free, no obligation case review.

*uk.reuters.com/article/2014/02/13/us-boehringer-pradaxa-idUKBREA1C0PW20140213, Reuters, February 13, 2014

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

http://www.pradaxalawsuithelp.com/

https://plus.google.com/115936073311125306742?rel=author

For the original version on PRWeb visit: http://www.prweb.com/releases/pradaxa-lawsuit/pradaxa-bleeding/prweb11587264.htm


Source: prweb



comments powered by Disqus